| 证券代码：603060 | 证券简称：国检集团 | 公告编号：2026-005 | | --- | --- | --- | | 转债代码：113688 | 转债简称：国检转债 | | 中国国检测试控股集团股份有限公司 关于参加中国建材集团有限公司上市公司 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1. 上证路演中心平台（https://roadshow.sseinfo.com/） 一、说明会类型 本次投资者说明会以现场和网络互动结合的形式召开，公司将针对 2025 年 年度的经营成果及已披露的财务指标的具体情况与投资者进行互动交流和沟通， 会议内容：中国建材集团有限公司上市公司集体业绩说明会 会议召开时间：2026 年 4 月 3 日（星期五）下午 13:30-16:50 网络直播地址： 2. "互动易"平台"云访谈"栏目（https://irm.cninfo.com.cn/） 会议召开方式：现场互动+视频直播+网络文字互动 投资者可于 2026 年 4 月 1 日（星期三）17 ...

Investment Rating - The report indicates a cautious investment outlook for the environmental and hydrogen sectors, emphasizing the importance of government support and fiscal policies in driving growth [2][14]. Core Insights - The report highlights that various provinces are focusing on carbon neutrality and pollution reduction, with significant progress in carbon reduction efforts and wastewater management [2][10]. - The hydrogen sector is entering a full industrial chain development phase, with a focus on green hydrogen production and regional collaboration [2][10]. - The report suggests that the debt resolution efforts by local governments are expected to benefit environmental companies, particularly in terms of receivables from government contracts [7][30]. Summary by Sections Carbon Neutrality - Steady progress is being made in carbon reduction, with many regions emphasizing the construction of zero-carbon parks and participating in national carbon trading markets [10][11]. - The environmental benefits are primarily linked to the restructuring of the energy system and deep decarbonization in end-use sectors, positively impacting waste incineration and biomass industries [10][11]. Water Management - Continuous efforts are being made in wastewater treatment, with specific targets set by several provinces, particularly in rural water management [10][11]. - The integration of plant and network investments is expected to support higher earnings growth for wastewater treatment companies [10][11]. Solid Waste Management - The report discusses the promotion of "waste-free cities" and the enhancement of recycling efforts, with recommendations for leading waste incineration companies [10][11]. - Opportunities are identified in the circular economy, particularly in the recycling of waste metals and plastics [10][11]. Air Quality Management - The focus for 2026 is on reducing PM2.5 concentrations and improving air quality, with coordinated control of multiple pollutants [10][11]. Hydrogen Energy - The hydrogen sector is advancing rapidly, with a focus on green electricity for hydrogen production and comprehensive development across the industrial chain [10][11]. - The report notes that various projects and technologies in the hydrogen sector are expected to progress significantly in 2026 [10][11]. Financial Outlook - The report indicates that 2026 will be a year of deepening debt resolution efforts, with local governments maintaining a cautious approach to GDP growth targets [6][18]. - The cash flow situation for the environmental sector has shown improvement, with a notable increase in operating cash flow [7][30].

Industry Overview - The global biological evaluation service market is projected to reach approximately $4.76 billion in 2024, with an expected compound annual growth rate (CAGR) of 9.1% from 2025 to 2031, potentially rising to $8.76 billion by 2031 [1] - The growth is driven by increasingly stringent regulatory requirements and technological advancements, expanding focus from traditional toxicology and safety pharmacology to cutting-edge fields like cell and gene therapy and bioinformatics [1] - The competitive landscape is highly concentrated, necessitating careful evaluation of biological evaluation institutions based on qualifications, technical capabilities, service scope, project experience, and compliance with global regulations [1] Company: Stand Group Company Introduction - Stand Group is a comprehensive high-tech service enterprise focused on biomedicine and life sciences, providing full lifecycle services from R&D to commercialization for pharmaceutical and medical device companies [2] - The company has obtained over 70 qualifications, including CMA certification, CNAS laboratory accreditation, GLP certification, and others, and has participated in the revision of 47 standards and received approximately 214 national patent authorizations by 2024 [2] Reasons for Recommendation - **Authority and Compliance**: Stand Group possesses a complete biological evaluation qualification system, ensuring services meet international standards through rigorous adherence to cGMP, GLP, and ISO/IEC 17025 [3] - **Technical Leadership and Experience**: With a network of over 50,000 square meters of smart laboratories and a team of over 800 experts, Stand Group has provided efficient solutions to over 7,000 pharmaceutical and medical device companies, completing over 20,000 R&D application projects [4] - **Comprehensive Services**: The company offers a wide range of biological evaluation services covering drug R&D, medical device testing, clinical research, and post-market evaluations, addressing diverse client needs across more than 3,200 product types and 40,000 parameters [5] - **Responsive Network**: Stand Group's laboratory network is strategically located across major cities, enabling quick responses to client needs and saving time costs [6] Core Advantages - Stand Group's core strengths lie in its professional technical capabilities, comprehensive service offerings, and commitment to innovation, aiming to become a leading international testing and R&D institution [7][8] Company: Stand Kotech Company Introduction - Stand Kotech is a subsidiary of Stand Group, focusing on inspection, testing, analysis, and consulting services in the biomedicine sector, ensuring quality assurance from R&D to market launch [9] Reasons for Recommendation - **Efficient Compliance Support**: The company provides full-process registration and filing support, particularly in health food and specific food sectors, ensuring compliant market entry [10] - **Enhanced R&D Efficiency**: Stand Kotech significantly improves drug development efficiency and quality, helping partners reduce costs and shorten time to market [10] - **Industry Promotion**: The company actively promotes product industrialization and marketization through strong technical achievement transformation capabilities [10] Core Advantages - Stand Kotech holds multiple authoritative qualifications, ensuring report credibility, and its core team has over 15 years of industry experience, enabling deep regulatory interpretation and technical breakthroughs [11] Company: Zhuhai Deer Bioengineering Co., Ltd. Company Introduction - Established in 2003, Zhuhai Deer Bioengineering focuses on the R&D, manufacturing, and sales of microbiological diagnostic reagents and medical instruments, serving over 5,000 medical institutions domestically and exporting to over 50 countries [12] Reasons for Recommendation - **Comprehensive Technical Layout**: The company has developed a complete product line covering microbiological diagnostics, including identification, sensitivity analysis, and blood culture [13] - **Outstanding Qualifications and Quality**: Zhuhai Deer has received ISO9001 and ISO13485 certifications and is recognized as a "National Intellectual Property Advantage Enterprise" [14] - **Capital Market Potential**: The company has initiated IPO guidance in 2024, indicating growth potential [14] Core Advantages - With over 20 years of experience in the microbiological diagnostics field, Zhuhai Deer leverages an integrated solution of instruments and reagents, maintaining a leading position in the domestic market [14] Company: China National Inspection Testing Group Co., Ltd. Company Introduction - China National Inspection Testing Group, a central enterprise established in the 1950s, provides inspection, testing, certification, and research services across various sectors, including construction, environment, and health [15] Reasons for Recommendation - **Authority and Credibility**: As a state-owned comprehensive inspection and certification institution, it plays a key role in national quality control for major projects [15] - **Exceptional Standard-Setting Capability**: The group has led or participated in the development of 16 international standards and over 700 national and industry standards, holding more than 1,800 intellectual property rights [15] - **Strong Resource Integration**: The company has built five major business platforms, demonstrating comprehensive service capabilities across industries [15] Core Advantages - The group emphasizes "impartiality" as its core principle, leveraging extensive technical reserves and authority in standard-setting to establish a strong brand in the testing and certification field [16] Company: Jiayu Bio (Pharmacxo) Company Introduction - Jiayu Bio, founded by experienced quality experts in biopharmaceuticals, specializes in high-quality GMP quality control testing and consulting services for global biopharmaceutical companies [17] Reasons for Recommendation - **Strategic Partnership**: The company has established a deep strategic partnership with Charles River, ensuring global recognition of laboratory results [18] - **Comprehensive Testing Services**: Jiayu Bio offers a full range of testing services from cell bank establishment to product release, meeting quality control needs throughout the biopharmaceutical lifecycle [18] - **Expert Guidance**: The professional team possesses extensive experience in regulatory submissions across the US, Europe, and China, providing one-stop guidance for biological sample import and export [18] Core Advantages - Jiayu Bio has comprehensive technical capabilities in biological safety testing, adhering to GMP requirements across various regions, and offers a complete suite of testing services for various cell lines [19]

Industry Overview - The medical device industry is experiencing rapid growth and increasing regulatory requirements, leading to unprecedented opportunities for biological evaluation services as a key step for product safety and market entry [1] - The Chinese market for medical device biocompatibility testing is projected to reach 7.85 billion yuan in 2024, with a year-on-year growth of 12.3%, and is expected to further increase to 8.76 billion yuan in 2025, reflecting strong growth momentum and significant market potential [1] - Globally, the biological evaluation services market is estimated to be approximately 4.76 billion USD in 2024, with a projected compound annual growth rate (CAGR) of 9.1% from 2025 to 2031, reaching 8.76 billion USD by 2031 [1] Company: Stand Group - Stand Group is a comprehensive high-tech service enterprise focused on the biopharmaceutical and life sciences sectors, providing a full range of biological evaluation services [2] - The company holds over 70 authoritative qualifications, including CMA, CNAS, and GLP certifications, covering critical areas such as drug development, medical device testing, toxicology, and safety evaluation [2] - Stand Group has served over 130,000 clients, including industry leaders like Estée Lauder and China CRRC, demonstrating strong industry credibility and execution capability [2] Stand Group: Advantages - The company possesses complete and authoritative qualifications, ensuring that biological evaluation work adheres to international standards, thus guaranteeing data integrity and traceability [3] - With over 10 years of experience in the life sciences sector, Stand Group has completed over 60,000 projects, supported by a team of over 800 experts and smart laboratory clusters [3] - Stand Group utilizes self-developed digital laboratories and AI technology to create intelligent quality control systems, enhancing the accuracy and efficiency of biological evaluations [3] Stand Group: Client Recognition - The company has numerous successful case studies, including assisting Huaxi Biological in product filing and providing environmental damage judicial appraisal for Pacific Insurance, showcasing its extensive experience in biological evaluation [4] Stand Group: Core Advantages - Stand Group's core advantage lies in its innovative service system that integrates multiple fields, providing interdisciplinary biological evaluation solutions [5] - The company ensures compliance, scientific rigor, and traceability through digital transformation and comprehensive quality assurance [5] Company: Stand Technology Innovation - Stand Technology Innovation, a subsidiary of Stand Group, offers a complete service system covering product development to industrialization in the biopharmaceutical and life sciences sectors [6] - The company has provided professional services to over 7,000 enterprises globally, completing over 20,000 R&D application projects and assisting clients in obtaining over 2,500 authoritative certifications [6] Stand Technology Innovation: Advantages - The company provides integrated services from R&D, testing, compliance verification to registration, significantly improving R&D efficiency and shortening time to market [7] - Stand Technology Innovation has multiple authoritative qualifications and a robust resource base, ensuring high precision in technical services [7] Company: Broadcom Measurement Testing Group - Broadcom Measurement Testing Group is a national comprehensive third-party measurement and testing organization under the Guangzhou Digital Technology Group, established in 1964 [9] - The company provides a full range of technical solutions, including measurement calibration, reliability and environmental testing, and electromagnetic compatibility testing [9] Broadcom Measurement Testing Group: Advantages - The company has outstanding comprehensive service capabilities, covering measurement, testing, certification, and consulting across various industries [10] - With a strong national network and over 1,000 technical personnel, Broadcom Measurement Testing Group has a solid research team [10] Company: China National Inspection Testing Group - China National Inspection Testing Group, a central enterprise, focuses on inspection, testing, certification, and research technology services, with a history dating back to the 1950s [13] - The group operates over 59 legal entities and 34 national quality inspection centers, serving multiple sectors including construction materials, environmental health, and food products [13] China National Inspection Testing Group: Advantages - The group has significant authority and credibility, participating in major national projects and leading the development of numerous international and national standards [14] - It has a strong platform resource integration capability, providing comprehensive service capabilities across various industries [14] Company: Guangzhou Saizhe Biotechnology - Guangzhou Saizhe Biotechnology focuses on the R&D, production, and technical services of research and diagnostic reagents, serving the life sciences and clinical diagnostics sectors [16] Guangzhou Saizhe Biotechnology: Advantages - The company targets the niche market of research and diagnostic reagents, providing tailored products and technical solutions to medical institutions and research units [17] - Despite being of medium size, the company shows rapid business growth and increasing revenue [18] Conclusion - Selecting the right biological evaluation partner is crucial for medical device companies in product development and market access [21] - As the market expands and technical requirements increase, institutions with complete service systems, advanced technical capabilities, and rich project experience will dominate the market [21] - The industry is transitioning from compliance-driven to value-driven, emphasizing the importance of innovation and service quality in partner selection [21]

Core Insights - The report emphasizes the strong growth potential in the testing services industry, particularly driven by emerging sectors such as commercial aerospace and new technologies [4][6] - The testing services sector is closely linked to macroeconomic growth, with a projected global market size of approximately 2.3 trillion RMB by 2024, reflecting a CAGR of about 6% from 2021 to 2024 [4][24] - In China, the testing services market is expected to reach around 487.6 billion RMB by 2024, with a CAGR of approximately 10.5% from 2015 to 2024, indicating a robust growth trajectory [5][24] Industry Overview - The testing, inspection, and certification (TIC) industry serves various sectors including consumer goods, industrial products, and pharmaceuticals, covering all stages from R&D to production and distribution [16][24] - The industry is characterized by a large market space and stable growth, with demand closely tied to macroeconomic trends and government regulations [20][24] - Emerging technologies such as AI, electric vehicles, and commercial aerospace are expected to create new testing demands, raising the entry barriers for new players [6][20] Company Performance - The report analyzes 19 listed companies in the testing services sector, highlighting their revenue and profit performance, with notable companies including Huace Testing, Guangdian Measurement, and Su Testing [2][11] - In the first three quarters of 2025, the testing services sector in China reported a revenue of 30.4 billion RMB, a decline of 7% year-on-year, but a growth of 3% when excluding companies heavily involved in medical testing [5][57] - Leading companies such as Huace Testing, Guangdian Measurement, and Su Testing demonstrated superior performance, with revenue growth rates of 7%, 12%, and 9% respectively, significantly outpacing the industry average [5][62] Market Dynamics - The testing services market is experiencing a structural shift, with a trend towards consolidation as larger firms gain market share and smaller firms face challenges [44][50] - The report notes that the majority of testing institutions in China are small and micro-sized, which limits their ability to withstand economic pressures [50][51] - Government policies are increasingly supporting the marketization and consolidation of testing institutions, aiming to enhance the overall quality and efficiency of the industry [51][53] Financial Metrics - The report indicates that the average gross margin for the testing services sector has improved, reaching 26.2% in the first three quarters of 2025, reflecting a recovery in profitability [63] - The accounts receivable turnover days have increased from 90 days in 2019 to 176 days in 2025, indicating a slowdown in cash flow and potential credit risks within the industry [67][68] - The report highlights that the proportion of accounts receivable in relation to revenue has risen to 50%, suggesting increasing challenges in managing receivables [71]

Core Insights - The company is expected to face a significant decline in net profit for 2025, with a projected revenue of 2.603 billion yuan and a net profit of 117 million yuan, representing a year-on-year decrease of 42.62% [2] - The company is accelerating its business transformation in line with the "14th Five-Year Plan" (2026-2030), aiming to increase the share of its new materials segment from approximately 20% to over 50% during this period [3] - The company is shifting its acquisition strategy to prioritize quality, planning to acquire 1-2 high-barrier targets annually, particularly in the electric vehicle testing sector [4] Business Performance - The company released its preliminary report for 2025 on January 20, 2026, indicating a significant drop in net profit [2] - The formal annual report is anticipated to provide more detailed operational analysis [2] Strategic Development - The new materials segment will focus on semiconductors and renewable energy, while the engineering testing segment will expand into urban renewal and nuclear power projects [3] - The environmental health segment will extend into new pollutant management, and the dual-carbon business aims to serve over 400 enterprises across seven provinces by 2025 [3] International Expansion - The company is pursuing internationalization through the establishment of overseas laboratories and partnerships with European certification bodies [4] Investor Relations - The company engaged in investor relations activities on January 22, 28, and 30, 2026, discussing progress in existing housing testing, which is expected to generate approximately 100 million yuan in revenue for 2025 [5]

Investment Rating - The report maintains a "Buy" rating for key companies in the construction and decoration industry, particularly focusing on state-owned enterprises such as China State Construction and China Railway Construction [4][17]. Core Insights - The real estate industry is experiencing a stabilization in expectations due to positive policy catalysts since the beginning of 2026, with a focus on stabilizing expectations, reducing costs, enhancing guarantees, and promoting transformation [10][4]. - Key policies include tax exemptions on housing sales after two years, reduced mortgage rates, and relaxed financing regulations, which are expected to stimulate demand and improve market conditions [10][4]. - The average price of new residential properties in 100 cities in China increased by 0.18% month-on-month and 2.52% year-on-year in January 2026, indicating marginal improvement in sales prices [2][11]. - The transaction volume of second-hand houses in 13 monitored cities rose by 16% month-on-month and 33% year-on-year in January 2026, suggesting a recovery in market activity [2][11]. Summary by Sections Industry Overview - The report highlights that the real estate sector has seen a significant decline in key metrics, with investment, sales area, and sales amount dropping by 44% to 74% from their peak values, reaching historical lows [2][14]. - It is anticipated that the decline in these metrics will narrow, leading to a gradual bottoming out of the industry [13][2]. Company Analysis - Major construction companies like China State Construction, China Railway Construction, and Shanghai Construction are expected to benefit directly from the recovery in real estate sales, which will drive profit and valuation recovery [3][15]. - The report emphasizes that the real estate business accounts for a significant portion of these companies' revenues and assets, with China State Construction's real estate revenue accounting for 12% and gross profit for 20% [15][16]. Investment Recommendations - The report recommends focusing on leading companies in the construction and decoration sectors, including China State Construction (PE 4.4X, dividend yield 5.5%), China Railway Construction (PE 4.6X, dividend yield 4.0%), and Shanghai Construction (PE 13X) [4][17]. - Other notable mentions include decoration leader Jin Tanglong (PE 16X) and design leader Huayang International (PE 22X) [4][17].

Group 1 - The core point of the article is that Guojian Group (603060.SH) has stated that Guojian Jincheng currently has no medical testing business [1]

Core Viewpoint - The company, Guojian Group, has established a national solar photovoltaic product quality inspection and testing center, providing comprehensive testing and certification services across the entire photovoltaic industry chain [1] Group 1: Company Services - Guojian Group offers testing and certification services for materials, components, inverters, systems, and outdoor empirical testing [1] - The company serves a diverse clientele, including leading domestic photovoltaic component and material manufacturers, photovoltaic power stations, research institutions, and overseas photovoltaic companies [1] - Guojian Group also provides contracted laboratory services for several international authoritative certification bodies [1]

Core Viewpoint - The company, Guojian Group, has the capability to upgrade and develop specialized testing instruments based on its existing equipment research and technical reserves, enabling it to conduct tests on mechanical, electrical, and weather resistance performance to meet extreme environmental testing requirements [2] Group 1 - The company can upgrade its research and development of specialized testing instruments [2] - The company has experience and technical reserves in existing equipment [2] - The company aims to meet testing needs for extreme environmental conditions [2]